173 related articles for article (PubMed ID: 36206780)
41. Treatment of fibrotic interstitial lung disease: current approaches and future directions.
Johannson KA; Chaudhuri N; Adegunsoye A; Wolters PJ
Lancet; 2021 Oct; 398(10309):1450-1460. PubMed ID: 34499866
[TBL] [Abstract][Full Text] [Related]
42. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
[TBL] [Abstract][Full Text] [Related]
43. Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview.
Mackintosh JA; Stainer A; Barnett JL; Renzoni EA
Semin Respir Crit Care Med; 2019 Apr; 40(2):208-226. PubMed ID: 31137061
[TBL] [Abstract][Full Text] [Related]
44. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.
Fischer A; Distler J
Clin Rheumatol; 2019 Oct; 38(10):2673-2681. PubMed ID: 31423560
[TBL] [Abstract][Full Text] [Related]
45. A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease.
Ryerson CJ; Corte TJ; Myers JL; Walsh SLF; Guler SA
Eur Respir J; 2021 Dec; 58(6):. PubMed ID: 34140296
[TBL] [Abstract][Full Text] [Related]
46. End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study.
Ahmadi Z; Wysham NG; Lundström S; Janson C; Currow DC; Ekström M
Thorax; 2016 Jun; 71(6):510-6. PubMed ID: 26865603
[TBL] [Abstract][Full Text] [Related]
47. Ability of the COPD Assessment Test to evaluate the lung-specific quality of life in systemic sclerosis-associated interstitial lung disease.
Mugii N; Someya F
Clin Respir J; 2020 Jun; 14(6):527-532. PubMed ID: 32045097
[TBL] [Abstract][Full Text] [Related]
48. Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic.
Guiot J; Henket M; Frix AN; Delvaux M; Denis A; Giltay L; Thys M; Gester F; Moutschen M; Corhay JL; Louis R;
Respir Investig; 2020 Nov; 58(6):437-439. PubMed ID: 32978099
[TBL] [Abstract][Full Text] [Related]
49. Role of the internet of medical things in care for patients with interstitial lung disease.
Nakshbandi G; Moor CC; Wijsenbeek MS
Curr Opin Pulm Med; 2023 Jul; 29(4):285-292. PubMed ID: 37212372
[TBL] [Abstract][Full Text] [Related]
50. Management of interstitial lung disease associated with connective tissue disease.
Mathai SC; Danoff SK
BMJ; 2016 Feb; 352():h6819. PubMed ID: 26912511
[TBL] [Abstract][Full Text] [Related]
51. Home-based initiatives for acute management of COVID-19 patients needing oxygen: differences across The Netherlands.
Boeijen JA; van de Pol AC; van Uum RT; Smit K; Ahmad A; van Rijswijk E; van Apeldoorn MJ; van Thiel E; de Graaf N; Menkveld RM; Mantingh MR; Geertman S; Couzijn N; van Groenendael L; Schers H; Bont J; Bonten TN; Rutten FH; Zwart DLM
BMC Health Serv Res; 2023 Nov; 23(1):1257. PubMed ID: 37968634
[TBL] [Abstract][Full Text] [Related]
52. Identification and Remediation of Environmental Exposures in Patients With Interstitial Lung Disease: Evidence Review and Practical Considerations.
Copeland CR; Collins BF; Salisbury ML
Chest; 2021 Jul; 160(1):219-230. PubMed ID: 33609518
[TBL] [Abstract][Full Text] [Related]
53. Assisting People With Their Living, Not Their Dying: Health Professionals' Perspectives of Palliative Care and Opioids in ILD.
Russo L; Willis K; Smallwood N
Am J Hosp Palliat Care; 2022 Feb; 39(2):211-219. PubMed ID: 34056929
[TBL] [Abstract][Full Text] [Related]
54. Advancing Symptom Alleviation with Palliative Treatment (ADAPT) trial to improve quality of life: a study protocol for a randomized clinical trial.
Graney BA; Au DH; Barón AE; Cheng A; Combs SA; Glorioso TJ; Paden G; Parsons EC; Rabin BA; Ritzwoller DP; Stonecipher JJ; Turvey C; Welsh CH; Bekelman DB
Trials; 2019 Jun; 20(1):355. PubMed ID: 31196156
[TBL] [Abstract][Full Text] [Related]
55. Smoking-related interstitial lung disease.
Hagmeyer L; Randerath W
Dtsch Arztebl Int; 2015 Jan; 112(4):43-50. PubMed ID: 25797422
[TBL] [Abstract][Full Text] [Related]
56. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
57. The opportunities and challenges of social media in interstitial lung disease: a viewpoint.
Grewal JS; Kawano-Dourado L; Ryerson CJ
Respir Res; 2021 Sep; 22(1):247. PubMed ID: 34535127
[TBL] [Abstract][Full Text] [Related]
58. Cancer patients' perspectives on remote monitoring at home during the COVID-19 pandemic- a qualitative study in Norway.
Leonardsen AL; Helgesen AK; Stensvold A; Magnussen J; Grøndahl VA
BMC Health Serv Res; 2022 Apr; 22(1):453. PubMed ID: 35387645
[TBL] [Abstract][Full Text] [Related]
59. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
[TBL] [Abstract][Full Text] [Related]
60. Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: a cross-sectional study.
Sato R; Handa T; Matsumoto H; Kubo T; Hirai T
BMC Pulm Med; 2019 Dec; 19(1):247. PubMed ID: 31842848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
